1. Home
  2. IDYA vs TPC Comparison

IDYA vs TPC Comparison

Compare IDYA & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$33.40

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Tutor Perini Corporation

TPC

Tutor Perini Corporation

HOLD

Current Price

$67.95

Market Cap

3.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
TPC
Founded
2015
1894
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
General Bldg Contractors - Nonresidential Bldgs
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.1B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IDYA
TPC
Price
$33.40
$67.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
3
Target Price
$49.42
$82.00
AVG Volume (30 Days)
926.1K
496.1K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
0.36%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$214,834,000.00
$5,103,323,000.00
Revenue This Year
$2,434.86
$25.77
Revenue Next Year
N/A
$14.81
P/E Ratio
N/A
N/A
Revenue Growth
5377.66
19.22
52 Week Low
$13.45
$18.34
52 Week High
$37.08
$77.00

Technical Indicators

Market Signals
Indicator
IDYA
TPC
Relative Strength Index (RSI) 51.57 55.23
Support Level $33.12 $65.58
Resistance Level $37.08 $70.77
Average True Range (ATR) 1.45 2.39
MACD -0.34 0.22
Stochastic Oscillator 13.64 65.94

Price Performance

Historical Comparison
IDYA
TPC

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: